Health Condition 1: null- Patients with cardiovascular disease
Conditions
Interventions
Intervention1: Clopidogrel: Since this study is planned as an observational study, the dosage of clopidogrel will not be manipulated for this study purpose. The patients will receive Clopidogrel thera
Sponsors
Indian Council of Medical Research
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients who are diagnosed with cardiovascular indications requiring treatment with clopidogrel as anti-platelet therapy. 2. Patients who are newly started on clopidogrel therapy and will be visiting cardiology department for follow-up.
Exclusion criteria
Exclusion criteria: 1. Clinically unstable patients 2. Patients who are already stabilized with clopidogrel monotherapy or combination therapy with aspirin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Percentage of the study population with genetic polymorphism of CYP2C19. 2. Percentage of the study population that is resistant to clopidogrel therapy. 3. Association between genetic polymorphism of CYP2C19 and clopidogrel resistance. Timepoint: Sampling time: Pre dose ( 0 day), Post dose - day 1, day 7-14 and day 25 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Level of drug (clopidogrel) and its metabolite in blood samples. 2. Relation between clopidogrel levels and Platelet aggregation in relation to CYP 3A4, CYP2C9 and P2Y12 polymorphism Timepoint: Sampling Time: Two or three samples post oral dosing | — |
Countries
India
Contacts
Public ContactDr M Surulivelrajan
Department of Pharmacy Practice, Manipal College of Pharmaceutical Science, Manipal University
Outcome results
None listed